Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

VOLUNTARY ANNOUNCEMENT
SIGNIFICANT PROGRESS ACHIEVED IN THE iMed-6.0 SERIES MEDICAL IMAGING LARGE MODEL

This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest technology update of the Group.

The Group continues to deepen its presence in medical imaging artificial intelligence. Through independent R&D of the iMedImage® foundation large model, it completed a full-modal architecture upgrade in the first half of 2026, and launched the iMedLoop™ medical imaging AI research and production acceleration platform in July of the same year. Relying on the large-scale and high-quality medical imaging data accumulated by the Group, through technological innovation in underlying algorithms, continuous training and expansion of the training scale, the medical imaging understanding and analysis capabilities of the Group's foundation model have been continuously enhanced. The board of directors (the "**Board**") of the Company is pleased to announce that the Group's latest-generation medical imaging large models, iMed-6.0 Thoth ("**Thoth**") and iMed-6.0 Aegis ("**Aegis**"), have achieved significant technological progress. These two models are the medium-parameter-scale and smaller-parameter-scale versions of the iMed-6.0 series, respectively.

The Group's iMed-6.0 series models have achieved globally leading results in both the globally renowned Massive Multi-discipline Multimodal Understanding and Reasoning ("**MMMU (Test)**"), and the full-modal large model evaluation of MedBench, a professional medical AI evaluation platform. MMMU (Test) covers six major areas including medicine, science and engineering, and 30 categories. According to the test results of the Group, Thoth ranked first with a comprehensive score across all areas higher than those of other models. The scores of Thoth and Aegis in the "Health and Medicine" sub-category ranked first and second globally, respectively, demonstrating their outstanding capabilities in medical multimodal understanding and reasoning, and further reflecting their potential for cross-disciplinary and multi-task generalization. According to the evaluation results obtained after the Group submitted its models to MedBench, the comprehensive scores of both Thoth and Aegis were higher than the highest scores of the models listed on the public leaderboard of full-modal large models during the same period, ranking first and second globally, respectively. Among them, Thoth scored 88.8 points in the "Medical Visual Perception and Text Extraction" sub-category, which was 20.3% higher than the previous highest score.

The general Computed Tomography ("**CT**") vertical model developed by the Group based on Aegis has achieved significant technological progress in the comprehensive analysis of multiple organs and multiple abnormalities in CT images. The model supports unenhanced and contrast-enhanced CT scans of the chest and abdomen. It can conduct comprehensive analyses of multiple organs and multiple categories of abnormalities within the scanning range of a single examination, covering 509 diseases and imaging signs. In the evaluation conducted by the Group using nearly 40,000 pairs of CT images and reports from multiple hospitals, the average Area Under the Curve ("**AUC**") (abnormality discrimination capability indicators, the closer to 1 the better) of the 249 key tasks selected by the Group reached 0.930. As a public research reference, disclosures of the RADAR study published in *Science* cover 146 abdominal imaging findings, with an average AUC of 0.895 validated across various centers. The average AUC of Aegis across all 509 tasks was 0.855.

To further enhance its core technological capabilities, the Group firmly believes that it is essential to establish more objective, comprehensive and highly challenging professional evaluation benchmarks that are closely aligned with clinical practice. The Group is continuously upgrading the self-established professional evaluation benchmark, DoctorBench. Through challenging medical tasks, it further accurately and comprehensively measures the models' medical imaging understanding, reasoning, and comprehensive application capabilities in complex scenarios. The Group plans to announce a new round of evaluation results in due course, including the relevant performance and R&D progress of iMed-6.0 Horus, the model of the Group with the largest parameter scale.

The Board believes that the continuous improvement in the capabilities of the foundation model is an important driving force for enhancing the core competitiveness of the Group's "model factory" and expanding commercialization space. A stronger foundation model is expected to improve the model development and training efficiency of iMedLoop™, accelerate the supply of specialized models tailored to different organs, diseases and application scenarios, and support medical experts in accelerating research and the verification of new methods. Meanwhile, relevant technological advancements are expected to accelerate the deployment and application of diagnostic models to the primary healthcare system, help medical institutions improve imaging reporting efficiency and accuracy through inference services, and drive the business expansion of per-case billing model inference services. With an increase in available models and service scenarios, the Group is expected to expand customer coverage and case service scale, promoting the transformation of technological advantages into sustained commercial value. The Group will continue to explore the upper limits of the foundation model's capabilities, strengthen training and professional evaluations, and is committed to accelerating the intellectualization of global medical imaging to enhance human health.

The above evaluation results reflect the model performance under specific data and conditions. There remain uncertainties in the application and commercialization of the relevant technologies.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Note: The comparison date for the public leaderboards of MedBench and MMMU Test is November 11, 2026. The above comparisons do not represent that the model of the Group has been published on the public leaderboards. The CT indicators are the macro-average AUC of zero-shot classification (an equal-weighted average of various tasks), which is not equivalent to diagnostic accuracy; the covered items of different studies are calculated according to their respective definitions, which does not constitute a direct comparison of model performance.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board, Executive Director and General Manager

Hangzhou, PRC, November 12, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.